The Government of Ontario’s Support for OmniaBio adds a $40 million contribution to the $540 million biomanufacturing project in Hamilton’s Life Sciences Sector.
Hamilton’s life sciences sector is positioned for another major success as Invest Ontario announced on March 31st, 2021 that they would be providing a $40 million contribution to the construction of OmniaBio’s $540 million biomanufacturing facility at the McMaster Innovation Park.
The investment is part of a strategy more than a decade in the making. In 2010, the Centre for Commercialization of Regenerative Medicine (CCRM), OmniaBio’s parent company, and the McMaster Innovation Park agreed to collaborate on the creation and commercialization of medical techniques focused on gene therapy, cell therapy, and other innovative medical technology.
On completion, the facility will become part of a biomanufacturing centre of excellence being built at McMaster Innovation Park. It will leverage CCRM/OmniaBio’s existing capabilities by providing Phase III and commercial-scale manufacturing of gene-modified cell therapies and viral vectors, while also offering the flexibility to pivot to other advanced therapies in emergencies.
The site will further support the development of Hamilton’s life science workforce through the facilitation of on-site training via the Canadian Advanced Therapies Training Institute – a partnership between CCRM and Montreal-based CellCAN. It is expected that the site will employ more than 250 highly-skilled workers when it shifts into full-scale production.